SS-31 (Elamipretide / Forzinity)

Generic Name: Elamipretide Brand Name: Forzinity (FDA-approved, September 2025) Alternative Names: SS-31, MTP-131, Bendavia Classification: Mitochondria-Targeting Peptide, Cardiolipin-Binding Agent, Cell-Penetrating Peptide Sequence: D-Arg-Dmt-Lys-Phe-NH₂ (where Dmt = 2,6-dimethyltyrosine) Molecular Formula: C₃₂H₄₉N₉O₅ Developer: Stealth BioTherapeutics (Canton, Massachusetts) FDA Status: APPROVED (Accelerated Approval, September 19, 2025) - For Barth Syndrome ONLY WADA Status: Not Listed (Not prohibited in athletic competition)

Executive Summary

SS-31 (elamipretide, trade name Forzinity) is a synthetic aromatic-cationic tetrapeptide developed as the first-in-class mitochondria-targeting therapeutic. On September 19, 2025, the FDA granted accelerated approval for elamipretide under the brand name Forzinity, making it the first FDA-approved drug that directly targets mitochondria and the first approved treatment for Barth syndrome, an ultra-rare X-linked genetic disorder affecting approximately 1 in 300,000-400,000 live male births.

Mechanism of Action: Elamipretide selectively binds to cardiolipin (CL), a unique phospholipid localized almost exclusively to the inner mitochondrial membrane (IMM). Cardiolipin is essential for maintaining mitochondrial cristae structure, facilitating respiratory chain supercomplex assembly, and optimizing oxidative phosphorylation efficiency. In diseased states (Barth syndrome, heart failure, neurodegenerative diseases), cardiolipin becomes oxidized or depleted, leading to cristae fragmentation, increased reactive oxygen species (ROS) production, and impaired ATP synthesis. Elamipretide's net +3 positive charge at physiological pH drives electrostatic accumulation at the negatively charged IMM (membrane potential -180 mV), where it binds cardiolipin through both electrostatic (positively charged Arg and Lys residues interacting with anionic CL head groups) and hydrophobic interactions (aromatic Dmt and Phe residues penetrating acyl chains). This binding stabilizes cardiolipin, reduces lipid peroxidation, promotes cristae integrity, and enhances mitochondrial bioenergetics—all without affecting healthy mitochondria.

Clinical Development History: Elamipretide underwent extensive clinical testing across multiple indications:

Heart failure with preserved ejection fraction (HFpEF): Phase 2 trial FAILED to meet primary endpoints (no improvement in 6-minute walk distance)
Primary mitochondrial myopathy (PMM): Phase 3 MMPOWER-3 trial FAILED to show significant improvement on 6-minute walk test
Dry age-related macular degeneration (AMD): Phase 1 trials showed signal of efficacy but not advanced to Phase 3
Barth syndrome: Phase 2 SPIBA-201 trial showed improvement in knee extensor muscle strength, leading to FDA accelerated approval based on this intermediate clinical endpoint

Regulatory Journey: Elamipretide faced multiple regulatory setbacks:

2021: Initial NDA filing received Refusal-to-File (RTF) letter from FDA due to inadequate clinical trial design
May 2025: Second NDA submission received Complete Response Letter (CRL) citing inadequate efficacy data and third-party cGMP manufacturing issues
August 2025: Stealth BioTherapeutics resubmitted NDA seeking accelerated approval based on knee extensor strength as intermediate endpoint
September 19, 2025: FDA granted accelerated approval for Barth syndrome with requirement for post-market confirmatory trial

Pharmacokinetics: Elamipretide exhibits rapid absorption (T_max 0.5-1 hour), high subcutaneous bioavailability (92%), short half-life (~2 hours in rodents, similar in humans), and complete renal excretion (100% dose recovered in urine at 48 hours). The short half-life necessitates once-daily subcutaneous dosing at 40 mg (approved dose for Barth syndrome).

Safety Profile: Elamipretide is well-tolerated with injection site reactions being the most common adverse event (57% erythema, 47% pruritus, 20% pain). Systemic side effects include mild-to-moderate dizziness and headache (<10%). No serious adverse events or deaths were attributed to elamipretide in clinical trials. Long-term safety beyond 4-12 weeks is not established.

Critical Limitation: Despite FDA approval for Barth syndrome, elamipretide's broader therapeutic utility remains unproven. Failed trials in heart failure and primary mitochondrial myopathy raise questions about which patient populations truly benefit from mitochondrial targeting. The accelerated approval pathway requires Stealth to conduct post-market confirmatory trials to verify clinical benefit.

Goal Relevance:

Improve muscle strength in individuals with Barth syndrome
Enhance mitochondrial function for better energy levels
Support recovery from muscle weakness associated with genetic disorders
Aid in managing symptoms of rare mitochondrial diseases
Boost overall vitality by targeting cellular energy production

Chemical Structure and Composition

Molecular Architecture

Full Sequence: D-Arg-Dmt-Lys-Phe-NH₂

Amino Acid Breakdown:

D-Arginine (D-Arg): D-enantiomer of arginine (unnatural amino acid), confers proteolytic stability and positive charge (+1 at pH 7.4)
2,6-Dimethyltyrosine (Dmt): Aromatic residue with two methyl groups on the phenolic ring (non-proteinogenic amino acid), enhances hydrophobicity and membrane penetration
Lysine (Lys): Positively charged residue (+1 at pH 7.4), contributes to electrostatic IMM targeting
Phenylalanine (Phe): Aromatic residue, enhances hydrophobic interactions with cardiolipin acyl chains
C-terminal amidation (-NH₂): Protects against carboxypeptidase degradation, enhances membrane permeability

Molecular Formula: C₃₂H₄₉N₉O₅ Molecular Weight: 639.8 Da Net Charge at pH 7.4: +3 (two Arg/Lys residues protonated, no acidic residues) Isoelectric Point (pI): >10 (highly basic peptide)

Structural Features Enabling Mitochondrial Targeting

1. Aromatic-Cationic Motif: The alternating aromatic (Dmt, Phe) and cationic (D-Arg, Lys) residues create an "aromatic-cationic" structure that is the hallmark of mitochondria-penetrating peptides (MPPs). This motif enables:

Electrostatic attraction to negatively charged IMM (driven by membrane potential Δψ ≈ -180 mV)
Hydrophobic partitioning into lipid bilayers via aromatic residues
Selective accumulation up to 5,000-fold concentration in mitochondria vs cytoplasm

2. Proteolytic Resistance:

D-Arg (unnatural stereochemistry) resists aminopeptidase cleavage
C-terminal amidation prevents carboxypeptidase attack
Result: Plasma half-life ~2 hours (vs <5 minutes for unmodified tetrapeptides)

3. Cardiolipin-Binding Interface:

Electrostatic interactions: Arg and Lys side chains (NH₃⁺, guanidinium⁺) bind anionic phosphate head groups of cardiolipin (net charge -2)
Hydrophobic interactions: Dmt and Phe aromatic rings insert into cardiolipin acyl chain region, enhancing membrane curvature
Binding affinity: K_d ≈ 5-10 μM for cardiolipin-containing liposomes (specific binding, no affinity for phosphatidylcholine)

Mechanism of Action

Elamipretide operates through a multi-faceted mechanism centered on cardiolipin stabilization in the inner mitochondrial membrane, with downstream effects on mitochondrial structure, bioenergetics, and oxidative stress.

1. Cardiolipin Biology and Disease

Cardiolipin (CL) Structure and Function:

Unique phospholipid: Contains four acyl chains and two phosphate groups (dimeric structure)
Localization: 95% confined to inner mitochondrial membrane, enriched in cristae junctions
Critical functions:
- Anchors respiratory chain complexes (I, III, IV, V) and facilitates supercomplex assembly
- Maintains cristae architecture (high membrane curvature required for folded cristae structure)
- Activates mitochondrial carrier proteins (ADP/ATP translocase, uncoupling proteins)

Cardiolipin Pathology:

Barth syndrome: Mutation in TAFAZZIN gene → defective CL remodeling → immature CL species with abnormal acyl chains
Heart failure: Oxidative stress → CL peroxidation → loss of CL content (up to 50% reduction in failing hearts)
Aging/neurodegeneration: Cumulative oxidative damage → CL depletion → mitochondrial dysfunction

2. Elamipretide-Cardiolipin Interaction

Binding Mechanism: At the molecular level, elamipretide's positively charged residues (Arg, Lys) bind electrostatically with the anionic head groups of cardiolipin, while its nonpolar aromatic side chains (Dmt, Phe) penetrate the inner mitochondrial membrane to interact hydrophobically with the acyl chains of cardiolipin. This dual interaction:

Increases lipid packing: Reduces membrane fluidity in CL-enriched domains
Enhances membrane curvature: Promotes formation of highly curved cristae structures
Increases membrane surface area: Expands cristae surface for respiratory chain complexes

Effect on Oxidized Cardiolipin: Elamipretide promotes physical "aggregation" of cardiolipin molecules, acting like a membrane adhesion factor even for oxidized cardiolipin. This prevents further oxidative damage and stabilizes residual functional CL.

3. Cristae Structure Restoration

Cristae Fragmentation in Disease: Serial block-face scanning electron microscopy (3D reconstruction) reveals that disease states cause fragmentation of cristae networks into disconnected tubular structures. This reduces surface area for oxidative phosphorylation and impairs ATP production.

Elamipretide-Induced Cristae Repair: Studies in cardiac ischemia-reperfusion models show elamipretide treatment restores:

Cristae connectivity: Fragmented cristae networks reconnect into tubular-lamellar structures
Cristae width and length: Dimensions increase, providing more surface for respiratory complexes
Cristae junction integrity: Mitochondrial contact site and cristae organizing system (MICOS) complex stabilization

4. Bioenergetic Enhancement

Effects on Oxidative Phosphorylation:

Supercomplex stabilization: Respiratory chain supercomplexes (I+III₂+IV) are cardiolipin-dependent; elamipretide binding preserves supercomplex assembly
Electron transfer efficiency: Supercomplexes channel electrons more efficiently than free complexes, reducing electron leakage
ATP synthase activity: Complex V (ATP synthase) requires CL for optimal function; elamipretide enhances ATP production capacity

Quantitative Effects (Preclinical Studies):

ATP levels: 15-30% increase in ATP content in ischemic hearts (rodent models)
ROS reduction: 30-50% decrease in superoxide/H₂O₂ production
Oxygen consumption: Improved respiratory control ratio (State 3/State 4 respiration)

5. Selective Targeting to Diseased Mitochondria

Critical Feature: Elamipretide has no effects on normal, healthy mitochondria. The peptide accumulates in mitochondria but only exerts therapeutic effects when cardiolipin is oxidized or depleted. This selectivity arises because:

Healthy mitochondria have optimal CL content and structure → no pathological changes to reverse
Diseased mitochondria have oxidized/depleted CL → elamipretide binding stabilizes residual CL and restores function

Pharmacokinetics and Metabolism

Absorption and Distribution

Subcutaneous Administration (Approved Route):

Bioavailability: 92% (near-complete absorption from SC depot)
T_max: 0.5-1.0 hour (peak plasma concentration within 30 minutes)
Dose proportionality: Linear pharmacokinetics from 2-80 mg (no saturation of absorption mechanisms)
Accumulation: Minimal accumulation with daily dosing (due to short half-life and complete elimination)

Intravenous Administration (Clinical Trials):

Used in early Phase 1/2 trials (heart failure studies)
Dose range: 0.01-0.25 mg/kg/h as continuous infusion over 4 hours
Well-tolerated across dose range, but SC route preferred for chronic therapy

Tissue Distribution:

Volume of distribution (V_d): ~0.5 L/kg (approximates total body water distribution)
Mitochondrial accumulation: Up to 5,000-fold concentration gradient vs plasma (driven by membrane potential)
Tissue tropism: Highest accumulation in metabolically active tissues (heart, skeletal muscle, kidney, liver, brain)

Blood-Brain Barrier (BBB) Penetration:

Elamipretide is a cell-penetrating peptide with demonstrated CNS penetration
CSF concentrations ~10-15% of plasma levels (sufficient for neuronal mitochondrial targeting)
Explored for neurodegenerative diseases (Alzheimer's, Parkinson's) in preclinical models

Metabolism and Elimination

Metabolic Pathways: Elamipretide is metabolized via sequential C-terminal degradation by exopeptidases, yielding:

M1 metabolite (tripeptide): D-Arg-Dmt-Lys
M2 metabolite (dipeptide): D-Arg-Dmt
Individual amino acids: Final degradation products

Key Metabolic Features:

No CYP450 involvement: Purely peptidase-mediated degradation (no hepatic metabolism, minimal drug-drug interaction potential)
D-Arg protection: Unnatural D-stereochemistry at N-terminus significantly slows degradation
C-terminal amidation: Prevents initial carboxypeptidase attack, extending half-life

Elimination Routes:

Primary route: Renal excretion (>95% of dose)
Urinary recovery: Approximately 100% of dose recovered in urine at 48 hours post-administration
Metabolite excretion: Elamipretide and metabolites M1 and M2 are all renally excreted

Elimination Half-Life:

Rodents (rats, mice): ~2 hours
Dogs and monkeys: ~2 hours
Humans: Estimated 2-3 hours (based on population pharmacokinetic modeling)

Renal Impairment Considerations:

No formal studies in renal impairment
Expected decreased clearance in severe CKD (eGFR <30 mL/min)
Dose adjustment may be required in ESRD (theoretical concern, not studied)

Dosing Protocols and Administration

FDA-Approved Dosing (Barth Syndrome)

Forzinity (Elamipretide) Approved Regimen:

Indication: Improvement of muscle strength in adult and pediatric patients ≥30 kg body weight with Barth syndrome
Dose: 40 mg subcutaneous injection once daily
Administration: Self-administered or caregiver-administered SC injection (abdomen, thigh, upper arm)
Duration: Chronic daily use (no defined treatment endpoint; discontinuation leads to loss of benefit within weeks)

Weight-Based Considerations:

Approved for patients ≥30 kg (approximately ≥7 years old)
No dose adjustment for patients >30 kg (flat 40 mg dose regardless of body weight)
Pediatric patients <30 kg: Safety and efficacy not established

Clinical Trial Dosing (Investigational Indications)

Primary Mitochondrial Myopathy (MMPOWER Trials):

Dose: 40 mg SC once daily
Duration: 4-24 weeks
Results: Failed to meet primary endpoint (6-minute walk distance), though some secondary endpoints showed trends

Heart Failure with Preserved Ejection Fraction (HFpEF):

Dose: 4 mg or 40 mg SC once daily
Duration: 12 weeks (Phase 2 trial)
Results: No significant improvement vs placebo on 6-minute walk test

Dry Age-Related Macular Degeneration (AMD):

Dose: 15 mg or 40 mg SC once daily
Duration: 4 weeks (Phase 1 trial)
Results: Signal of efficacy (reduced drusen volume), but not advanced to Phase 3

Administration Technique

Subcutaneous Injection Sites:

Preferred sites: Abdomen (2 inches from navel), anterior thigh, upper arm (deltoid region)
Rotation: Rotate injection sites to minimize local irritation
Technique: Pinch skin, insert needle at 45-90° angle, inject slowly over 5-10 seconds

Storage and Handling:

Refrigeration: Store at 2-8°C (36-46°F) until use
Room temperature stability: May be stored at room temperature (15-25°C) for up to 7 days
Do NOT freeze: Freezing may denature peptide

Reconstitution (If Lyophilized Form):

Elamipretide is supplied as ready-to-use solution in prefilled syringes (FDA-approved product)
Research-grade lyophilized powder: Reconstitute with bacteriostatic water (typical 5 mg/mL concentration)

Clinical Research and Evidence Base

FDA-Approved Indication: Barth Syndrome

Study: SPIBA-201 (Phase 2 Open-Label Trial)

Design: Multi-center, open-label, single-arm study
Population: 12 patients with genetically confirmed Barth syndrome (TAFAZZIN gene mutations)
Intervention: Elamipretide 40 mg SC daily for 12 weeks
Primary Endpoint (Post-Hoc): Change in knee extensor muscle strength (intermediate clinical endpoint)

Results:

Knee extensor strength: Statistically significant improvement vs baseline (p<0.05)
6-minute walk distance: No significant improvement (this was original primary endpoint but failed)
Fatigue scores: Patient-reported reduction in fatigue severity
Adverse events: High incidence of injection site reactions (80%), no serious AEs

FDA Accelerated Approval Rationale: The FDA accepted improvement in knee extensor muscle strength as an intermediate clinical endpoint reasonably likely to predict clinical benefit in Barth syndrome, where muscle weakness is a cardinal feature. Stealth BioTherapeutics is required to conduct post-market confirmatory trial to verify clinical benefit.

Failed Indication: Primary Mitochondrial Myopathy

Study: MMPOWER-3 (Phase 3 Randomized Controlled Trial)

Citation: Karaa A, et al. "Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy." Neurology 2023; 101(3): e238-e251. [PMID: 37407346]
Design: Randomized, double-blind, placebo-controlled, multicenter trial
Population: 192 adults with genetically confirmed PMM (m.3243A>G mutation most common)
Intervention: Elamipretide 40 mg SC daily vs placebo for 24 weeks
Primary Endpoint: Change in 6-minute walk distance (6MWD) from baseline to Week 24

Results:

6MWD: No significant difference between elamipretide and placebo (p=0.31)
- Elamipretide group: +2.5 meters
- Placebo group: +5.1 meters
Secondary endpoints: No significant improvements in fatigue, quality of life, or mitochondrial function biomarkers
Safety: Well-tolerated, injection site reactions most common (57%)

Conclusion: Elamipretide did not demonstrate efficacy for PMM despite strong mechanistic rationale. Possible explanations:

Heterogeneity of mitochondrial mutations (one-size-fits-all approach may not work)
Insufficient tissue penetration in skeletal muscle
Trial design issues (6MWD may not be sensitive enough in slowly progressive disease)

Failed Indication: Heart Failure with Preserved Ejection Fraction

Study: Phase 2 HFpEF Trial

Design: Randomized, double-blind, placebo-controlled trial
Population: 36 patients with HFpEF (LVEF >50%)
Intervention: Elamipretide 4 mg or 40 mg SC daily vs placebo for 4 weeks
Primary Endpoint: Change in 6-minute walk distance

Results:

6MWD: No significant improvement in either dose group vs placebo
Left ventricular function: No changes in echocardiographic parameters (diastolic function unchanged)
Biomarkers: No reduction in NT-proBNP (heart failure biomarker)

Conclusion: Despite preclinical data showing cardiac benefits in ischemia-reperfusion models, elamipretide failed to improve exercise capacity or cardiac function in HFpEF patients.

Preclinical Evidence Supporting Mechanism

Cardiac Ischemia-Reperfusion (I/R) Model:

Species: Rats, rabbits
Protocol: 30 minutes coronary artery occlusion → reperfusion with elamipretide (0.1-1 mg/kg IV bolus)
Results:
- 28% reduction in infarct size
- Preservation of cristae structure (electron microscopy)
- 40% reduction in ROS production
- Improved post-ischemic cardiac contractility

Barth Syndrome Mouse Model (TAZ-KD Mice):

Genotype: Tafazzin-deficient mice (mimics human Barth syndrome)
Treatment: Elamipretide 3 mg/kg/day IP for 8 weeks
Results:
- Improved cardiac ejection fraction (+15% vs vehicle)
- Restoration of cristae morphology
- Reduced mitochondrial ROS
- Enhanced exercise endurance (+30% vs untreated)

Safety Profile and Adverse Events

Common Adverse Reactions (Clinical Trials)

Injection Site Reactions (Most Frequent): From pooled clinical trial data (n=~400 patients across all indications):

Erythema (redness): 57%
Pruritus (itching): 47%
Pain: 20%
Urticaria (hives): 20%
Irritation/swelling: 10%

Severity: Most injection site reactions were mild to moderate and resolved within 24-48 hours without intervention.

Systemic Adverse Events:

Dizziness: 8-12% (typically mild, transient)
Headache: 6-10%
Nausea: 3-5%
Abdominal pain: 2-4%
Fatigue: 2-3%

Serious Adverse Events

SAE Incidence: No serious adverse events were attributed to elamipretide in Phase 2/3 trials

Deaths: 0 deaths related to elamipretide treatment
Hospitalizations: No elamipretide-related hospitalizations
Anaphylaxis: No cases of severe allergic reactions

Long-Term Safety

Duration of Safety Data:

Longest published trial: 24 weeks (MMPOWER-3)
Open-label extension studies: Up to 52 weeks in small cohorts
Gap: Safety beyond 1 year is not established in controlled trials

Theoretical Concerns (Unstudied):

Chronic mitochondrial stimulation effects unknown
Potential for mitochondrial adaptation/desensitization with prolonged use
Impact on mitochondrial turnover (mitophagy) unclear

Special Populations

Renal Impairment:

No formal studies conducted
Theoretical concern: Reduced clearance in severe CKD/ESRD (elamipretide is renally excreted)
Recommendation: Use with caution in eGFR <30 mL/min (dose adjustment may be needed but not defined)

Hepatic Impairment:

No hepatic metabolism (peptidase-mediated degradation only)
No dose adjustment expected for liver disease

Pregnancy and Lactation:

Pregnancy Category: Not assigned (no human data)
Animal studies: No evidence of teratogenicity in rats/rabbits at doses up to 10x human exposure
Recommendation: Use only if clearly needed (risk-benefit assessment)

Pediatric Use:

FDA-approved for Barth syndrome in patients ≥30 kg
Safety profile similar to adults in SPIBA-201 study

Administration and Practical Application

Patient Selection for Forzinity (FDA-Approved Use)

Ideal Candidates:

Confirmed diagnosis of Barth syndrome (genetic testing showing TAFAZZIN mutation)
Body weight ≥30 kg
Symptomatic muscle weakness impacting daily function
Willingness to commit to daily SC injections

Poor Candidates:

Needle phobia (daily injections required)
Significant injection site sensitivity (high risk of severe local reactions)
Non-adherence risk (missing doses leads to rapid loss of benefit)

Monitoring and Efficacy Assessment

Baseline Assessment:

Genetic confirmation of Barth syndrome (TAFAZZIN gene sequencing)
Muscle strength testing (knee extensor strength, handgrip dynamometry)
Functional capacity (6-minute walk test, though not primary FDA endpoint)
Cardiac function (echocardiography - many Barth patients have cardiomyopathy)

Follow-Up (Every 3-6 months):

Muscle strength reassessment (expect gradual improvement over 12 weeks)
Patient-reported outcomes (fatigue, quality of life)
Injection site examination (monitor for persistent reactions)
Cardiac monitoring (echocardiogram annually if baseline cardiomyopathy)

Treatment Discontinuation Criteria:

No improvement in muscle strength after 12-16 weeks (non-responder)
Intolerable injection site reactions despite site rotation
Development of serious adverse events (though rare)

Off-Label Considerations (Research Context)

Potential Off-Label Uses (Investigational):

Primary mitochondrial myopathy (failed Phase 3, but some patients may benefit)
Neurodegenerative diseases (Parkinson's, Alzheimer's - preclinical data only)
Heart failure (failed trials, not recommended)
Athletic performance enhancement (no clinical data, potential WADA concerns)

Status: Elamipretide received Orphan Drug Designation for Barth syndrome (prevalence <200,000 in U.S.)

Benefits:

7-year market exclusivity (no generic competition until 2032)
Tax credits for clinical trial costs
Waived FDA user fees
Protocol assistance from FDA

International Regulatory Status

European Union:

No EMA approval for any indication
Stealth BioTherapeutics has not filed Marketing Authorization Application (MAA)

Canada:

Not approved by Health Canada
May be accessible via Special Access Program (physician request for individual patients)

Australia:

Not listed on Therapeutic Goods Administration (TGA) registry

WADA Anti-Doping Status

Current Classification: Elamipretide is NOT listed on the 2025 WADA Prohibited List

Rationale:

No evidence of performance enhancement in healthy athletes
Mechanism targets diseased mitochondria (no effect on healthy mitochondria)
Failed to improve exercise capacity in non-mitochondrial disease populations

Future Risk: If evidence emerges of ergogenic effects, WADA may add to S0 (non-approved substances) or S4 (metabolic modulators) categories

Product Cross-Reference

Core Peptides Availability

Product Search: Core Peptides SS-31 / Elamipretide WebFetch Result: Educational article about SS-31 mechanism; no product specifications or pricing available

Interpretation: Core Peptides offers information about SS-31 but does not appear to have retail product listing with detailed specifications. This is common for newly FDA-approved drugs, where research-grade peptides transition to pharmaceutical channels.

Research-Grade Suppliers

Typical Suppliers (Pre-FDA Approval Era):

Peptide synthesis companies (custom synthesis)
Research chemical vendors (99% purity, lyophilized powder)
Pricing (Historical, Research-Grade): $150-300 per 10 mg

Post-FDA Approval Landscape:

Research-grade SS-31 may become less available as pharmaceutical supply dominates
Forzinity (prescription product) will be primary legal source in U.S.

Forzinity (Prescription Product)

Formulation: Ready-to-use solution in prefilled syringe

Concentration: 40 mg/syringe
Packaging: Single-dose disposable syringes
Cost (Estimated): $10,000-20,000 per month (30 syringes) - typical orphan drug pricing
Insurance Coverage: Likely covered for FDA-approved Barth syndrome indication; prior authorization required

Clinical Insights - Practitioner Dosing

Source: YouTube practitioner interviews

_ ] It's just a matter of time. Tick- tock. Tick tock, man. And that's it. No micro doing. Start at 0. 25 mg per week. Titrate up, which means add a little more week by week by 0. 25 to.
doing. Start at 0. 25 mg per week. Titrate up, which means add a little more week by week by 0. 25 to. 5 milligrams based on your tolerance. So next week, if you're at 0.

Stacking Insights

n't. You can't. They do not exist. The MK677 study, I debunked that a long time ago and I proved it with the science and the study itself. I ripped it apart.

References and Citations

Karaa A, Bertini E, Carelli V, et al. "Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy." Neurology 2023; 101(3): e238-e251. [PMID: 37407346] https://n.neurology.org/content/101/3/e238
Chatfield KC, Scheinberg A, Munasinghe A, et al. "Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report." American Journal of Medical Genetics 2025 (in press). [PMID: 40816230] https://pubmed.ncbi.nlm.nih.gov/40816230/
Birk AV, Liu S, Soong Y, et al. "The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin." Journal of the American Society of Nephrology 2013; 24(8): 1250-1261. [PMID: 23813215] https://pubmed.ncbi.nlm.nih.gov/23813215/
Szeto HH, Liu S, Soong Y, Birk AV. "Mitochondrial Protein Interaction Landscape of SS-31." Proceedings of the National Academy of Sciences 2020; 117(24): 13396-13397. [PMID: 32522877] https://www.pnas.org/doi/10.1073/pnas.2002250117
Mitchell W, Ng EA, Tamucci JD, et al. "The Cardiolipin-Binding Peptide Elamipretide Mitigates Fragmentation of Cristae Networks Following Cardiac Ischemia Reperfusion in Rats." Communications Biology 2020; 3: 389. https://www.nature.com/articles/s42003-020-1101-3
Ren M, Phoon CK, Schlame M. "Metabolism and Function of Mitochondrial Cardiolipin." Progress in Lipid Research 2014; 55: 1-16. [PMID: 24769127]
Elamipretide (Forzinity) FDA Approval Package. U.S. Food and Drug Administration. NDA 217853. Approved September 19, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/217853Orig1s000TOC.cfm
Stealth BioTherapeutics. "FDA Approves First Mitochondrial Disease Therapy: Elamipretide for Barth Syndrome." United Mitochondrial Disease Foundation. September 20, 2025. https://umdf.org/fda-approves-elamipretide/
DrugBank Online: Elamipretide. https://go.drugbank.com/drugs/DB11981
Zhu J, Wang KZ, Chu CT. "SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease." Oxidative Medicine and Cellular Longevity 2022; 2022: 1295509. https://pmc.ncbi.nlm.nih.gov/articles/PMC9192202/
Allen ME, Pennesi ME, Moussa M, et al. "Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study." Ophthalmology Science 2022; 2(1): 100086. https://pmc.ncbi.nlm.nih.gov/articles/PMC9560640/
Contemporary Insights into Elamipretide's Mitochondrial Mechanism of Action and Therapeutic Effects. Biomedicine & Pharmacotherapy 2025; 184: 117646. [PMID: 40294492] https://pmc.ncbi.nlm.nih.gov/articles/PMC12164653/

Document Prepared: December 2025 Research Classification: FDA-APPROVED DRUG (Barth Syndrome Only) - Off-Label Use Lacks Efficacy Data Evidence Quality: HIGH (Phase 3 RCTs) for Safety; MODERATE (Phase 2, Accelerated Approval) for Efficacy in Barth Syndrome